Simultaneous analysis of aliskiren and hydrochlorothiazide in pharmaceutical preparations and spiked human plasma by HPTLC

Publication date: Available online 13 May 2016 Source:Journal of Taibah University for Science Author(s): Jui J. Pandya, Nejal M. Bhatt, Vijay D. Chavada, Primal Sharma, Mallika Sanyal, Pranav S. Shrivastav A simple, selective and precise method based on HPTLC has been developed for the simultaneous determination of aliskiren and hydrochlorothiazide in a fixed-dose tablet formulation and human plasma. The chromatography was performed on silica gel 60 GF254 plates, with a mobile phase consisting of methanol–chloroform (6:4, v/v). Densitometric analysis of the analytes was carried out at 225nm. Under optimized conditions, the R f values were 0.26±0.02 and 0.71±0.02, and the resulting regression plots were linear (r 2 ≥0.9997) in the concentration ranges of 1.00–10.0 and 0.10–1.00μgband−1 for aliskiren and hydrochlorothiazide. The limit of detection and limit of quantitation of the validated method were 0.206 and 0.624μgband−1 for aliskiren and 0.015 and 0.046μgband−1 for hydrochlorothiazide, respectively. The % expected content of aliskiren and hydrochlorothiazide in the commercial tablet formulation was 99.2% and 101.3%, respectively. For spiked plasma sample preparation, the analytes and nebivolol internal standard were extracted from 500μL of plasma sample by solid-phase extraction on LiChrosep® DVB-HL cartridges. The mean extraction recovery of aliskiren and hydrochlorothiazide from human plasma was 87.2% and 76.5%, respectively. In ...
Source: Journal of Taibah University for Science - Category: Science Source Type: research